Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.44
$0.51(10.41%)
At close: 4:00 PM EST
$1.44
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.15 - $2.57
Previous CloseN/A
Volume28.07K
Average Volume (3M)874.96K
Market Cap
$76.61M
Enterprise Value$502.00M
Total Cash (Recent Filing)$917.55K
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Aug 13, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding44,538,105
10 Day Avg. Volume1,247,655
30 Day Avg. Volume874,956
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap6.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.39K
Enterprise Value/Ebitda-14.46
Forecast
1Y Price Target
$8.67Price Target Upside501.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$2.67M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressA formal EMA rolling review and regulator alignment on primary endpoints create a clearer pathway to conditional approval and coordinated global filings. This durable regulatory momentum reduces development uncertainty, supports planned Phase 3 timing and helps position OST-HER2 for market access and reimbursement planning.
Secured Near-Term FinancingThe secured convertible facility and initial tranche extend runway into 2027 and fund clinical and regulatory work. While dilutive, the financing materially improves near-term funding visibility, enabling late-stage development and manufacturing milestones needed to transition from a discovery-stage to a commercial-readiness company.
Improved Capital BaseDespite losses, the company shows a stronger capital base versus prior periods with meaningful assets and positive equity. That scale provides financial resources and optionality for development spending, partnering or manufacturing investments, supporting sustained program advancement over the medium term.
Bears Say
Pre-Revenue StatusOS Therapies remains clinical-stage with no commercial revenues; persistent negative gross profit and widening operating losses show the business is not yet self-sustaining. Long-term value depends entirely on successful clinical outcomes and approvals, making execution risk and binary trial results central to future viability.
Sustained Cash BurnOperating and free cash flow are consistently negative and worsened recently, indicating ongoing reliance on external capital to fund development. Even with new financing, persistent burn raises long-term dilution and financing risk and limits ability to self-fund multiple programs without strategic partnerships or additional financings.
Rising Leverage & Negative ROEMaterial uptick in leverage and deeply negative ROE indicate capital is not producing returns and increase financial fragility. Heavy debt levels can constrain strategic flexibility, magnify covenant and refinancing risk, and raise the cost of capital during critical late-stage development and potential commercialization ramps.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $76.61M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Aug 13, 2026 which is in 32 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on May 18, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.18.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 44,538,105 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.979%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (501.85% Upside)
$8.67 (501.85% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.61%
12-Months-Change
Fundamentals
Return on Equity
3214.88%
Trailing 12-Months
Asset Growth
71.75%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$8.67
▲(501.85% Upside)
Technical Analysis
Ownership Overview
8.31% Insiders
1.54% Mutual Funds
0.56% Other Institutional Investors
88.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---